查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933376

全球孕产妇健康治疗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Maternal Health Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

孕产妇健康治疗市场成长因素

受政府对孕产妇保健日益重视、女性健康项目投资增加以及妊娠併发症增加等因素的推动，全球孕产妇健康治疗市场在2025年呈现稳定成长态势。报告显示，全球孕产妇健康治疗市场预计在2025年达到46亿美元，从2026年的49.1亿美元成长至2034年的88.4亿美元，预测期内复合年增长率（CAGR）为7.63%。 北美地区在2025年将以42.32%的市场占有率领跑，这主要得益于其强大的医疗保健基础设施、不断增长的机构分娩率以及先进治疗手段的普及。

孕产妇健康治疗药物包括用于治疗妊娠併发症的药物，例如子痫前症、妊娠期糖尿病、产后出血和产后忧郁症，这些药物适用于孕前、怀孕和产后。生活方式相关疾病的增加、妊娠延迟以及分娩併发症的增多，都推动了对专业治疗方案的需求。此外，多家製药公司正在加强研发管线，以满足孕产妇保健领域尚未满足的需求。

市场动态

市场驱动因素

全球出生率的持续成长仍然是孕产妇健康治疗药物市场的主要驱动因素。不断增长的孕产妇人口直接扩大了妊娠相关併发症的风险族群，从而推动了对子宫收缩抑制剂、降血压药、胰岛素、抗生素和抗忧郁药物的需求。 机构分娩率的提高和医疗保健服务可近性的改善进一步支持了市场成长。

根据联合国儿童基金会（2023 年）的数据，全球将有约 1,321.1 亿新生儿出生，这凸显了对产科护理服务和药物日益增长的需求。

市场限制因子

一个主要的限制因素是妊娠专用药物的短缺。许多用于治疗孕产妇併发症的药物属于超适应症用药，是为一般人开发的。这种依赖性引发了人们对孕产妇安全、剂量优化和长期疗效的担忧。

2023 年 12 月，世界卫生组织 (WHO) 报告称，每年至少有 4,000 万名妇女遭受分娩带来的长期健康问题，这凸显了儘管疾病负担沉重，但治疗方面仍然存在缺口。

市场机会

产后护理领域的创新提供了巨大的成长机会。 产后疾病，如产后出血、忧郁症和感染，是促使孕产妇发病率和死亡率的重要因素，但这些疾病仍未得到充分治疗。

2023年12月，渤健公司与Sage Therapeutics公司合作，在美国推出了用于治疗成人产后忧郁症的药物Zurzuvae，这显示人们对产后药物的兴趣日益浓厚。

市场挑战

低收入国家孕产妇保健药物的可近性有限，这是一项重大挑战。薄弱的供应链、供应不稳定以及医疗基础设施的匮乏阻碍了药物的有效分发。

根据联合国儿童基金会（2024年）的数据，南苏丹、查德和索马利亚等国仍面临医疗设施严重短缺的问题，儘管需求不断增长，但这些国家获得基本孕产妇药物的机会仍然有限。

孕产妇健康治疗市场趋势

影响市场发展的关键趋势之一是政府对孕产妇保健的支持力度不断增加。世界各国政府正透过国家计画、资金支持计画和政策改革，将孕产妇安全放在首位。

2024年2月，美国卫生与公众服务部 (HHS) 启动了由部长领导的产后孕产妇健康合作项目，旨在解决产后死亡率问题，这标誌着政策层面的投入力度加大。

市场区隔分析

依药物类型划分，预计到2026年，不孕症药物将占市场主导地位，市占率达33.39%。同时，由于产后出血大量使用子宫收缩剂，荷尔蒙疗法也占了相当大的市场。 依适应症划分，预计妊娠期糖尿病将在 2026 年占 27.09% 的市场占有率，引领市场。产后出血在 2025 年占 15.7% 的市占率。依阶段划分，预计孕前阶段将在 2026 年占 42.25% 的市场占有率，而产后阶段预计将出现强劲增长。依给药途径划分，口服疗法预计在2026年将维持55.10%的市占率。依分销管道划分，医院药房将在2025年占主导地位，市场占有率达到50.8%，这主要得益于其在管理高风险孕产妇疾病方面发挥的作用。

区域展望

北美市场领先，预计2025年将达到19.5亿美元，2026年将达到20.8亿美元，这主要受产后忧郁症、子痫前症和妊娠期糖尿病病例增加的推动。欧洲市场预计在2025年将达到11.9亿美元，这得益于公众意识的提高和医疗保健投资的增加。亚太地区紧追在后，预计2025年将达到11.4亿美元，其次是拉丁美洲和中东及非洲，分别为1.9亿美元和6,000万美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家的监管环境
  • 主要公司的产品线分析
  • 主要疾病和主要国家的流行病学
  • 关键产业趋势：併购、业务合作、新产品发表等

第五章：全球孕产妇健康治疗市场分析：洞察与预测 (2021-2034)

  • 市场分析、洞察与预测：依药物类型划分
    • 荷尔蒙疗法
    • 促性腺激素释放激素 (GnRH) 调节剂
    • 疼痛管理/症状管理
    • 代谢疗法
    • 不孕症药物
    • 其他
  • 市场分析、洞察与预测：依适应症划分
    • 子痫前症/妊娠高血压
    • 妊娠糖尿病
    • 产后出血
    • 产后忧郁症
    • 妊娠剧吐
    • FNAIT（束状同种免疫性血小板减少症）
    • 产后子宫内膜炎
    • 其他
  • 市场分析、洞察与预测：依阶段
    • 怀孕前
    • 怀孕前
    • 围产期
    • 产后
  • 市场分析、洞察与预测：依给药途径
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测：依销售管道
    • 医院药房
    • 药局和零售药房
    • 线上药房
  • 市场分析、洞察与预测：依地区
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美孕产妇健康治疗市场分析：洞察与预测 （2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲孕产妇健康治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区孕产妇健康治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 东南亚亚洲
    • 澳大利亚
    • 亚太其他地区

第九章：拉丁美洲孕产妇健康治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲孕产妇健康治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）成员国
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025）
  • 公司简介
  • Novartis AG
  • Johnson &Johnson
  • Shionogi &Co., Ltd.
  • Bayer AG(Germany)
  • Bristol-Myers Squibb Company
  • Biogen
  • Pfizer Inc.
  • Merck &Co., Inc.,
Product Code: FBI114309

Growth Factors of maternal health therapeutics Market

The global maternal health therapeutics market demonstrated steady growth in 2025, supported by rising government focus on maternal healthcare, increasing investments in women's health programs, and a growing burden of pregnancy-related complications. According to the report, the global maternal health therapeutics market size was valued at USD 4.6 billion in 2025 and is projected to grow from USD 4.91 billion in 2026 to USD 8.84 billion by 2034, registering a CAGR of 7.63% during the forecast period. North America dominated the market with a 42.32% share in 2025, owing to strong healthcare infrastructure, higher institutional births, and greater access to advanced therapeutics.

Maternal health therapeutics include drugs used across preconception, pregnancy, labor & delivery, and postpartum stages to manage complications such as preeclampsia, gestational diabetes, postpartum hemorrhage, and postpartum depression. The rising prevalence of lifestyle-related disorders, delayed pregnancies, and increasing birth complications is driving demand for specialized therapeutic solutions. Additionally, several pharmaceutical companies are strengthening their pipelines to address unmet needs in maternal care.

Market Dynamics

Market Drivers

The rising number of births globally remains a major driver of the maternal health therapeutics market. An increasing maternal population directly expands the risk pool for pregnancy-related complications, driving demand for uterotonics, antihypertensives, insulin, antibiotics, and antidepressants. Growing institutional deliveries and improved access to healthcare services are further supporting market growth.

According to UNICEF (2023), approximately 132.11 billion births were reported globally, highlighting the expanding demand for maternal healthcare services and therapeutics.

Market Restraints

A key restraint is the lack of pregnancy-specific therapeutics. Many drugs used for maternal complications are off-label treatments initially developed for the general population. This reliance raises concerns related to safety, dosage optimization, and long-term outcomes for pregnant and postpartum women.

In December 2023, the World Health Organization (WHO) reported that at least 40.0 million women annually experience long-term health problems caused by childbirth, underscoring the existing treatment gap despite a high disease burden.

Market Opportunities

Innovation in postpartum care offers a major growth opportunity. Postpartum conditions such as hemorrhage, depression, and infections contribute significantly to maternal morbidity and mortality but remain underserved.

In December 2023, Biogen Inc., in collaboration with Sage Therapeutics, launched ZURZUVAE for the treatment of postpartum depression in adults in the U.S., highlighting the growing focus on postpartum therapeutics.

Market Challenges

Limited access to maternal health therapeutics in low-income countries poses a critical challenge. Weak supply chains, inconsistent availability, and poor healthcare infrastructure restrict effective drug distribution.

According to UNICEF (2024), countries such as South Sudan, Chad, and Somalia continue to face inadequate healthcare facilities, limiting access to essential maternal medicines despite growing demand.

Maternal Health Therapeutics Market Trends

An important trend shaping the market is increasing government support for maternal healthcare. Governments are prioritizing maternal safety through national programs, funding initiatives, and policy reforms.

In February 2024, the U.S. Department of Health and Human Services (HHS) launched the Secretary's Postpartum Maternal Health Collaborative to address postpartum mortality, reflecting rising policy-level commitment.

Segmentation Analysis

By drug type, fertility drugs are projected to dominate with a 33.39% share in 2026, while hormonal therapies hold a significant share due to high utilization of uterotonics for postpartum hemorrhage. By application, gestational diabetes is projected to lead with a 27.09% share in 2026, while postpartum hemorrhage accounted for 15.7% share in 2025. By phase, preconception is expected to account for 42.25% share in 2026, while the postpartum segment is anticipated to witness strong growth. By route of administration, oral therapies are projected to hold 55.10% share in 2026. By distribution channel, hospital pharmacies dominated with a 50.8% share in 2025, supported by their role in managing high-risk maternal conditions.

Regional Outlook

North America led the market with USD 1.95 billion in 2025 and USD 2.08 billion in 2026, driven by rising cases of postpartum depression, preeclampsia, and gestational diabetes. Europe reached USD 1.19 billion in 2025, supported by increasing awareness and healthcare investments. Asia Pacific followed with USD 1.14 billion in 2025, while Latin America and the Middle East & Africa recorded USD 0.19 billion and USD 0.06 billion, respectively.

Competitive Landscape

The market is semi-consolidated, with key players such as Johnson & Johnson, Novartis AG, Pfizer Inc., Biogen, and Merck & Co., Inc. focusing on collaborations, R&D investments, and strategic initiatives to expand their maternal health portfolios.

Conclusion

The global maternal health therapeutics market was valued at USD 4.6 billion in 2025 and is expected to grow from USD 4.91 billion in 2026 to USD 8.84 billion by 2034, driven by rising birth rates, increasing maternal complications, strong government support, and expanding pharmaceutical pipelines. North America maintained market leadership, while Europe and Asia Pacific demonstrated significant growth potential. Despite challenges such as limited access in low-income countries and reliance on off-label therapies, continued innovation in postpartum care, supportive government initiatives, and growing awareness of maternal health are expected to sustain market expansion through 2034.

Segmentation By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Region

By Drug Type * Hormonal Therapies

  • GnRH Modulators
  • Pain & Symptom Management
  • Metabolic Drugs
  • Fertility Drugs
  • Others

By Application * Preeclampsia & Gestational Hypertension

  • Gestational Diabetes
  • Postpartum Hemorrhage
  • Postpartum Depression
  • Hyperemesis Gravidarum
  • Alloimmune Thrombocytopenia (FNAIT)
  • Postpartum Endometritis
  • Others

By Phase * Preconception

  • Prenatal
  • Labor & delivery
  • Postnatal/ Postpartum

By Route of Administration * Oral

  • Parenteral

By Distribution Channel * Hospital Pharmacies

  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Geography * North America (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Epidemiology- Key Diseases, By Key Countries/ Regions
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Type
    • 5.1.1. Hormonal Therapies
    • 5.1.2. GnRH Modulators
    • 5.1.3. Pain & Symptom Management
    • 5.1.4. Metabolic Drugs
    • 5.1.5. Fertility Drugs
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Preeclampsia & Gestational Hypertension
    • 5.2.2. Gestational Diabetes
    • 5.2.3. Postpartum Hemorrhage
    • 5.2.4. Postpartum Depression
    • 5.2.5. Hyperemesis Gravidarum
    • 5.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 5.2.7. Postpartum Endometritis
    • 5.2.8. Others
  • 5.3. Market Analysis, Insights and Forecast - By Phase
    • 5.3.1. Preconception
    • 5.3.2. Prenatal
    • 5.3.3. Labor & Delivery
    • 5.3.4. Postnatal/ Postpartum
  • 5.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.4.1. Oral
    • 5.4.2. Parenteral
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Drug Stores & Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Type
    • 6.1.1. Hormonal Therapies
    • 6.1.2. GnRH Modulators
    • 6.1.3. Pain & Symptom Management
    • 6.1.4. Metabolic Drugs
    • 6.1.5. Fertility Drugs
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Preeclampsia & Gestational Hypertension
    • 6.2.2. Gestational Diabetes
    • 6.2.3. Postpartum Hemorrhage
    • 6.2.4. Postpartum Depression
    • 6.2.5. Hyperemesis Gravidarum
    • 6.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 6.2.7. Postpartum Endometritis
    • 6.2.8. Others
  • 6.3. Market Analysis, Insights and Forecast - By Phase
    • 6.3.1. Preconception
    • 6.3.2. Prenatal
    • 6.3.3. Labor & delivery
    • 6.3.4. Postnatal/ Postpartum
  • 6.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.4.1. Oral
    • 6.4.2. Parenteral
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Drug Stores & Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Type
    • 7.1.1. Hormonal Therapies
    • 7.1.2. GnRH Modulators
    • 7.1.3. Pain & Symptom Management
    • 7.1.4. Metabolic Drugs
    • 7.1.5. Fertility Drugs
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Preeclampsia & Gestational Hypertension
    • 7.2.2. Gestational Diabetes
    • 7.2.3. Postpartum Hemorrhage
    • 7.2.4. Postpartum Depression
    • 7.2.5. Hyperemesis Gravidarum
    • 7.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 7.2.7. Postpartum Endometritis
    • 7.2.8. Others
  • 7.3. Market Analysis, Insights and Forecast - By Phase
    • 7.3.1. Preconception
    • 7.3.2. Prenatal
    • 7.3.3. Labor & delivery
    • 7.3.4. Postnatal/ Postpartum
  • 7.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.4.1. Oral
    • 7.4.2. Parenteral
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Drug Stores & Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Type
    • 8.1.1. Hormonal Therapies
    • 8.1.2. GnRH Modulators
    • 8.1.3. Pain & Symptom Management
    • 8.1.4. Metabolic Drugs
    • 8.1.5. Fertility Drugs
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Preeclampsia & Gestational Hypertension
    • 8.2.2. Gestational Diabetes
    • 8.2.3. Postpartum Hemorrhage
    • 8.2.4. Postpartum Depression
    • 8.2.5. Hyperemesis Gravidarum
    • 8.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 8.2.7. Postpartum Endometritis
    • 8.2.8. Others
  • 8.3. Market Analysis, Insights and Forecast - By Phase
    • 8.3.1. Preconception
    • 8.3.2. Prenatal
    • 8.3.3. Labor & delivery
    • 8.3.4. Postnatal/ Postpartum
  • 8.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.4.1. Oral
    • 8.4.2. Parenteral
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Drug Stores & Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Southeast Asia
    • 8.6.5. Australia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Type
    • 9.1.1. Hormonal Therapies
    • 9.1.2. GnRH Modulators
    • 9.1.3. Pain & Symptom Management
    • 9.1.4. Metabolic Drugs
    • 9.1.5. Fertility Drugs
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Preeclampsia & Gestational Hypertension
    • 9.2.2. Gestational Diabetes
    • 9.2.3. Postpartum Hemorrhage
    • 9.2.4. Postpartum Depression
    • 9.2.5. Hyperemesis Gravidarum
    • 9.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 9.2.7. Postpartum Endometritis
    • 9.2.8. Others
  • 9.3. Market Analysis, Insights and Forecast - By Phase
    • 9.3.1. Preconception
    • 9.3.2. Prenatal
    • 9.3.3. Labor & delivery
    • 9.3.4. Postnatal/ Postpartum
  • 9.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.4.1. Oral
    • 9.4.2. Parenteral
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Drug Stores & Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Type
    • 10.1.1. Hormonal Therapies
    • 10.1.2. GnRH Modulators
    • 10.1.3. Pain & Symptom Management
    • 10.1.4. Metabolic Drugs
    • 10.1.5. Fertility Drugs
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Preeclampsia & Gestational Hypertension
    • 10.2.2. Gestational Diabetes
    • 10.2.3. Postpartum Hemorrhage
    • 10.2.4. Postpartum Depression
    • 10.2.5. Hyperemesis Gravidarum
    • 10.2.6. Alloimmune Thrombocytopenia (FNAIT)
    • 10.2.7. Postpartum Endometritis
    • 10.2.8. Others
  • 10.3. Market Analysis, Insights and Forecast - By Phase
    • 10.3.1. Preconception
    • 10.3.2. Prenatal
    • 10.3.3. Labor & delivery
    • 10.3.4. Postnatal/ Postpartum
  • 10.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.4.1. Oral
    • 10.4.2. Parenteral
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Drug Stores & Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Novartis AG
    • 11.2.2. Johnson & Johnson
    • 11.2.3. Shionogi & Co., Ltd.
    • 11.2.4. Bayer AG (Germany)
    • 11.2.5. Bristol-Myers Squibb Company
    • 11.2.6. Biogen
    • 11.2.7. Pfizer Inc.
    • 11.2.8. Merck & Co., Inc.,

List of Tables

  • Table 1: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 2: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 4: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 5: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 8: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 9: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 10: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 14: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 15: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase 2021-2034
  • Table 16: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 17: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 20: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 21: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 22: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 26: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 27: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 28: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
  • Table 32: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 33: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Phase, 2021-2034
  • Table 34: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 35: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Maternal Health Therapeutics Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Maternal Health Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025 & 2034
  • Figure 3: Global Maternal Health Therapeutics Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Maternal Health Therapeutics Market Value Share (%), by Phase 2025 & 2034
  • Figure 5: Global Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 6: Global Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Maternal Health Therapeutics Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Maternal Health Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 9: North America Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 10: North America Maternal Health Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 11: North America Maternal Health Therapeutics Market Value Share (%), by Application, 2025
  • Figure 12: North America Maternal Health Therapeutics Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 13: North America Maternal Health Therapeutics Market Value Share (%), by Phase, 2025
  • Figure 14: North America Maternal Health Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 15: North America Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 16: North America Maternal Health Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Maternal Health Therapeutics Market Value (USD billion), by Country, 2025 & 2034
  • Figure 19: North America Maternal Health Therapeutics Market Value Share (%), by Country, 2025
  • Figure 20: Europe Maternal Health Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 21: Europe Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 22: Europe Maternal Health Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 23: Europe Maternal Health Therapeutics Market Value Share (%), by Application, 2025
  • Figure 24: Europe Maternal Health Therapeutics Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 25: Europe Maternal Health Therapeutics Market Value Share (%), by Phase, 2025
  • Figure 26: Europe Maternal Health Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 27: Europe Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 28: Europe Maternal Health Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Maternal Health Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Maternal Health Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 33: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 34: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 35: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Application, 2025
  • Figure 36: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 37: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Phase, 2025
  • Figure 38: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 39: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 40: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Maternal Health Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Maternal Health Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 44: Latin America Maternal Health Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 45: Latin America Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 46: Latin America Maternal Health Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 47: Latin America Maternal Health Therapeutics Market Value Share (%), by Application, 2025
  • Figure 48: Latin America Maternal Health Therapeutics Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 49: Latin America Maternal Health Therapeutics Market Value Share (%), by Phase, 2025
  • Figure 50: Latin America Maternal Health Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 51: Latin America Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 52: Latin America Maternal Health Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Maternal Health Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Maternal Health Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Drug Type, 2025 & 2034
  • Figure 57: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Drug Type, 2025
  • Figure 58: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 59: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Application, 2025
  • Figure 60: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Phase, 2025 & 2034
  • Figure 61: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Phase, 2025
  • Figure 62: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 63: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 64: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Maternal Health Therapeutics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Maternal Health Therapeutics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 68: Global Maternal Health Therapeutics Market Share (%), by Company, 2025